-
Company Profile
![]()
BioLineRx Ltd – Company Profile
BioLineRx Ltd (BioLineRx) is a clinical-stage biopharmaceutical company that focuses on the development of products related to cancer and immunology. Its pipeline product BL-8040 is for the treatment of acute myeloid leukemia (AML) and relapsed or refractory AML. The company’s other pipeline drug candidate AGI-134 is synthetic alpha-gal immunotherapy that finds application in the treatment of solid tumors. BioLineRx's only product BL-5010 is a novel medical device indicated for the non-surgical removal of skin lesions. BioLineRx is headquartered in Modi'in-Maccabim-Re'ut,...
Add to Basket -
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – L-130 in Anxiety Disorders
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. L-130 in Anxiety Disorders Drug Details: L-130 is under development for the treatment of severe...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – ZKA-03 in Herpes Zoster (Shingles)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.ZKA-03 in Herpes Zoster (Shingles)Drug Details:ZK-A03 is under development for the treatment of herpes zoster (shingles)....
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – XTX-101 in Non-Small Cell Lung Cancer
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. XTX-101 in Non-Small Cell Lung Cancer Drug Details: XTX-101 is under development for the...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – RD-1302 in T-Cell Acute Lymphocytic Leukemia (T-Cell Acute Lymphoblastic Leukaemia)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. RD-1302 in T-Cell Acute Lymphocytic Leukemia (T-Cell Acute Lymphoblastic Leukaemia) Drug Details: RD13-02 is under...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – INV-202 in Diabetic Nephropathy
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. INV-202 in Diabetic Nephropathy Drug Details: INV-202 is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Atamparib in Mantle Cell Lymphoma
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.Atamparib in Mantle Cell Lymphoma Drug Details:Atamparib (RBN-2397) is under development for the treatment of advanced...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – AGI-134 in Sarcomas
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.AGI-134 in Sarcomas Drug Details:AGI-134 is under development for the treatment of solid tumors, metastatic colorectal...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – AGI-134 in Cervical Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.AGI-134 in Cervical Cancer Drug Details:AGI-134 is under development for the treatment of solid tumors, metastatic...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – AGI-134 in Endometrial Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.AGI-134 in Endometrial Cancer Drug Details:AGI-134 is under development for the treatment of solid tumors, metastatic...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – AGI-134 in Squamous Cell Carcinoma
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.AGI-134 in Squamous Cell Carcinoma Drug Details:AGI-134 is under development for the treatment of solid tumors,...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – AGI-134 in Solid Tumor
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.AGI-134 in Solid Tumor Drug Details:AGI-134 is under development for the treatment of solid tumors, metastatic...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – AGI-134 in Head And Neck Cancer Squamous Cell Carcinoma
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.AGI-134 in Head And Neck Cancer Squamous Cell Carcinoma Drug Details:AGI-134 is under development for the...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – AGI-134 in Metastatic Colorectal Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.AGI-134 in Metastatic Colorectal Cancer Drug Details:AGI-134 is under development for the treatment of solid tumors,...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – AGI-134 in Breast Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.AGI-134 in Breast Cancer Drug Details:AGI-134 is under development for the treatment of solid tumors, metastatic...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – AGI-134 in Melanoma
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.AGI-134 in Melanoma Drug Details:AGI-134 is under development for the treatment of solid tumors, metastatic colorectal...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – BNT-411 in Solid Tumor
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.BNT-411 in Solid Tumor Drug Details:SC-1 (BNT-411) is under development for the treatment of solid tumors...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – AGI-134 in Synovial Sarcoma
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.AGI-134 in Synovial SarcomaDrug Details:AGI-134 is under development for the treatment of solid tumors, metastatic colorectal...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – PF-07220060 in Colorectal Cancer
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. PF-07220060 in Colorectal Cancer Drug Details: PF-07220060 is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – GNOSPV-01 in Small-Cell Lung Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. GNOSPV-01 in Small-Cell Lung Cancer Drug Details: GNOSPV-01 is under investigation for the prevention of...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.